Clinical Trial Update: A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating adding Bevacizumab (Avastin) to carboplatin and paclitaxel in ovarian cancer; results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Avastin (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Taxol (paclitaxel)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Ovarian Cancer | Phase 3 | Status: COMPLETED | Results posted: 2016-06-10